News
3d
Motoring Research on MSNNew 911 Club Coupe marks 70 years of Porsche Club of AmericaLimited to 70 examples, the Porsche 911 Carrera T Club Coupe features bespoke paint and an optional tartan interior. The post ...
6d
MotorTrend on MSNThe 2026 Porsche 911 Carrera T Club Coupe Is a 70th Anniversary Love Letter to Porsche Club of AmericaBased on the lightweight 911 Carrera T, the Club Coupe's hardware remains unchanged. So there's a 388-hp twin-turbo flat-six, ...
Today, A' Design Award& Competition has released its call for entries to A' International Product Engineering and Technical Design Awards. The A' Product Engineering and Technical Design Awards are ...
Months after the Niskayuna school district voted to change its school nickname, the town has approved a new logo.
We recently published a list of 10 Surprising Stocks That Skyrocketed Today. In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other ...
Autodesk will launch a global campaign created by its new agency of record, Giant Spoon, during Round two of the NBA Playoffs this evening and it will continue to air through to games one and two ...
The bug with Windows 11 24H2 meant that Autodesk's AutoCAD 2022 application might fail to work - simply not launching - in some cases, and this could happen to any version.
If you like to be creative and you’re a fan of the Greene County Fair you might have the opportunity to attend this year’s fair for free – every day!
Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications.
In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $17.00.
Roughly 25 years after its debut, PayPal is “ushering in a new era for customers” with some generic black text. The company has a new logo, designed by Pentagram, and a new brand identity.
RBC Capital analyst Gregory Renza maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) yesterday and set a price target of $26.00. The company’s shares closed yesterday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results